Skip to main content
EN
  1. Learn the basics
  2. Find stocks
  3. Understand a stock

Intellia Therapeutics, Inc.

NTLA United States NASDAQ
Last Close: Market Cap: Currency: USD Reports in: Sector: Health Care Industry:

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

In short

Loading the key numbers…

What the sector means for this company

These sentences describe the numbers; they are not a recommendation. This content is not investment advice.

Price chart: each candle shows one day's opening, highest, lowest and closing price. The projection line is our model's estimate - a model, not a promise.

Price chart

Daily candles · prices in USD

View
Layers
From
To

Key statistics: the most used ratios in one place. Tap the icon next to a name for a short explanation. Compare them with similar companies, not with the whole market.

Financial statements: the income statement shows sales and profit, the balance sheet what the company owns and owes, and the cash flow statement the money that actually came in and went out. How to read them.

Company policy and leadership: an AI-assisted assessment of how the company sells, executes, uses its resources and treats people, production and service. Read it as a starting point for your own research.

News: the latest articles about the company, grouped by day. Each has ratings for the outlet's stance towards the company and how factual it is. What the ratings mean.